Medical Devices Contract Research Organizations Market (3rd Edition) by Target Therapeutic Area (Cardiovascular Disorders, CNS Disorders, Metabolic Disorders, Oncological Disorders, Ophthalmological Disorders, Orthopedic Disorders, Pain Disorders, Psychological Disorders, Respiratory Disorders, and Others), Scale of Operation (Clinical / Preclinical), Device Class (Class I, Class II, Class III), Type of Clinical Service Offered (Clinical Trial Management, Data Management, Regulatory Affairs Management, Consulting), Type of Preclinical Service Offered (Biocompatibility Testing, Sterility, Microbiology Testing, Material Characterization, Analytical Services), and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    August 2022

  • Pages
    552

  • View Count
    22600

Example Insights

Medical-Devices-Contract-Research-Organizations-Market-Context-thumb Medical-Devices-Contract-Research-Organizations-Market-Organizations-thumb Medical-Devices-Contract-Research-Organizations-Market-Device-Class-thumb Medical-Devices-Contract-Research-Organizations-Market-Peer-Groups-thumb
Medical-Devices-Contract-Research-Organizations-Market-Positioning-Analysis-thumb Medical-Devices-Contract-Research-Organizations-Market-Acquisitions-thumb Medical-Devices-Contract-Research-Organizations-Market-Trial-Analysis-thumb Medical-Devices-Contract-Research-Organizations-Market-Ownership-thumb
Medical-Devices-Contract-Research-Organizations-Market-Organizations-Market-thumb Medical-Devices-Contract-Research-Organizations-Market-services-offered-thumb

Overview

According to the World Health Organization (WHO), presently, around two million medical devices are available across the globe. Further, just over 35 medical devices received approval by the USFDA, every year. It is worth highlighting that, since 2020, the USFDA has approved around 105 medical devices. Moreover, the medical devices are expected to capture more than 40% of the global medtech industry and this value is projected to grow at a steady pace over the coming years. In this context, the number of medical device focused clinical trials have increased at a considerable rate, over the past few years. However, only a few players engaged in this domain claim to have the technical expertise to carry out in-house clinical research. This can be attributed to the high costs associated with acquiring the required infrastructure and capabilities to carry out research in this domain. In addition, various regulatory guidelines render medical devices subject to rigorous quality assessments, thereby, making it difficult for firms with limited finances to undertake research initiatives. Specifically, post the onset of the COVID-19 pandemic, there has been a substantial increase in the demand for medical devices as they have the ability to enable early diagnosis, as well as provide non-invasive and effective treatments. 

Given the surge in demand for medical devices in the recent past, coupled to the aforementioned constraints faced by developers, a large number of small, as well as well-established, players prefer to outsource a significant share of their respective clinical operations and regulatory affairs management to contract research organizations (CROs). Since 2010, over 75 CROs have been established in this domain. Further, in order to support the growing demand, medical device CROs have been re-evaluating and bolstering their existing capabilities to offer a wide range of services to their clients. Integration of novel technologies and tools, such as cloud computing, risk monitoring tools, real-world evidence and advanced data analytics, is another key initiative being undertaken by several CROs to distinguish themselves from their competitors. To enable expansion of their existing capabilities, more than 55 acquisitions and / or strategic alliances have been established by service providers in this market, since 2015. Considering the prevalent trends and projected opportunity associated with the overall medical devices market, we believe that the medical devices CROs market is likely to witness consistent grow, till 2035.

Scope of the Report

The ‘Medical Devices Contract Research Organizations Market (3rd Edition) by Target Therapeutic Area (Cardiovascular Disorders, CNS Disorders, Metabolic Disorders, Oncological Disorders, Ophthalmological Disorders, Orthopedic Disorders, Pain Disorders, Psychological Disorders, Respiratory Disorders, and Others), Scale of Operation (Clinical / Preclinical), Device Class (Class I, Class II, Class III), Type of Clinical Service Offered (Clinical Trial Management, Data Management, Regulatory Affairs Management, Consulting), Type of Preclinical Service Offered (Biocompatibility Testing, Sterility, Microbiology Testing, Material Characterization, Analytical Services), and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of the current market landscape and future opportunities associated with the medical device contract research organizations market. The study also includes an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

  • A detailed overview of the overall landscape of medical devices CROs, along with information on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World), area of specialization (medical device and in vitro diagnostics), device class (class I, class II, and class III), types of services offered by [A] clinical service providers  (biostatistics, consulting, clinical operations, post marketing surveillance / studies, quality assurance, regulatory affairs management, reimbursement and training), [B] preclinical service providers (consulting, biocompatibility testing, materials characterization and analytical testing, preclinical trials support, sterility testing and microbiology testing, and training) and [C] stand-alone service providers. 
  • An elaborate discussion on the various guidelines established and issued by major regulatory bodies for medical device approval, across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), and Asia-Pacific and Rest of the World (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). It also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe. 
  • Elaborate profiles of key players (shortlisted on the basis of the company competitiveness analysis) that specialize in offering services for both clinical and preclinical stage development of medical devices.. Each profile features a brief overview of the company, along with information on their year of establishment, number of employees, location of headquarters, key executives, medical device focused service portfolio, recent developments, and an informed future outlook.
  • An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers engaged in this domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.
  • A competitive benchmarking, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups (small, mid-sized and large players based in North America, Europe, Asia-Pacific, and Rest of the World), and providing a means for stakeholders to identify ways to gain a competitive advantage in the industry.
  • A detailed brand positioning analysis of leading industry players (shortlisted on the basis of revenues generated in 2021), highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as number of service(s) offered and device class.
  • An in-depth analysis of completed, ongoing, and planned clinical studies focused on medical devices, based on several relevant parameters, such as trial registration year, trial phase, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), target therapeutic area(s) and key geographical regions. 
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2022, based on several relevant parameters, such as year, type of agreements and geographical location of the companies. 
  • A detailed analysis of the total cost of ownership for a medical device contract research service provider. It features an informed estimate of direct and indirect expenses taking into consideration 19 relevant parameters, over a span of 20 years.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract research services to medical device developers. 
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics. 

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the medical devices contract research market over the coming years. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] target therapeutic area (Cardiovascular disorders, CNS disorders, Metabolic disorders, Oncological disorders, Ophthalmological disorders, Orthopedic disorders, Pain disorders, Psychological disorders, Respiratory disorders, and Others), [B] scale of operation (clinical and preclinical), [C] device class (class I, class II and class III), [D] types of clinical services offered (clinical trial management, consulting, data management, regulatory affairs management and others) [E] types of preclinical services offered (material characterization and analytical services, biocompatibility testing, sterility and microbiology testing and others), and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic tracks of the industry’s evolution. 

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following stakeholders: 

  • Lajos Sarosi (Chief Executive Officer and Co-founder, HungaroTrial)
  • Lee King (Senior Vice President, Business Development and Marketing)
  • Christopher Rupp (Vice President of Global Marketing and Commercial Operations, NAMSA)
  • Claus Hemiker (Head, Business Development)
  • Christian Wolflehner (General Manager, CW Research & Management)
  • Troy W. Mccall (Chief Commercial Officer, CROMSOURCE)
  • Nazish Urooj (Senior manager, Medical & Clinical Operations, Metrics Research)
  • C. Omprakash (Technical Director and Partner, Vyomus Consulting)
  • Tania Persson (Director of Business Development, A+ Science)
  • Alexa Foltin-Mertgen (Business Development Manager, AtoZ-CRO)  

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in offering contract research services for medical devices?
  • Which regions represent the key contract research hubs for medical devices?
  • What are the key regulatory guidelines, related to medical devices that have been established across various geographies?
  • What are the key value drivers of the merger and acquisition activity observed within this domain?
  • What percentage of the medical devices research operations are presently outsourced?
  • What are the likely future trends in contract research services market for medical devices?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What is the total cost of ownership required to set up a medical device contract research organization?

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured during our research. It offers a high-level view on the current state of the medical devices contract research market and its likely evolution in the short to mid-term and long term.

Chapter 3 provides a brief introduction to medical devices, highlighting the key historical and development milestones, and classification of such devices. It also provides a general overview of the concept of CROs, featuring a discussion on the historical evolution of contract research services market in the medical device domain. Further, it presents details related to the various types of CROs that operate within the medical device market and the different types of services offered. It further lists the advantages as well as challenges associated with outsourcing medical device research and clinical operations to contract service providers, along with the key parameters that need to be considered while selecting a CRO partner.

Chapter 4 features a detailed overview of the current market landscape of medical devices CROs, along with information on several relevant parameters, such as their year of establishment, company size (in terms of company size), location of headquarters (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World), area of specialization (medical device and in vitro diagnostics), device class (class I, class II, and class III), types of services offered by [A] clinical service providers  (biostatistics, consulting, clinical operations, post marketing surveillance / studies, quality assurance, regulatory affairs management, reimbursement and training), [B] preclinical service providers (consulting, biocompatibility testing, materials characterization and analytical testing, preclinical trials support, sterility testing and microbiology testing, and training) and [C] stand-alone service providers.

Chapter 5 features a discussion on the various guidelines established by major regulatory bodies for medical device approvals across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), and  Asia-Pacific and Rest of the World (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.  

Chapter 6 features detailed profiles of key players (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key executives, details related to contract research services offered, recent developments, and an informed future outlook.

Chapter 7 features an analysis on the key value drivers and performance indicators used by sponsor companies to evaluate service providers engaged in this domain, based on information gathered via secondary research (for top-ten medical device players), as well as credible inputs from primary research.

Chapter 8 presents a competitive benchmarking of the various players engaged in this domain. It highlights the capabilities of small-sized, mid-sized and large companies in terms of their expertise in medical device services. The analysis allows companies to compare their existing capabilities within and beyond their respective peer groups (small, mid-sized and large players based in North America, Europe, Asia-Pacific, and Rest of the World) and providing a means for stakeholders to identify ways to gain a competitive advantage in the industry.

Chapter 9 provides an elaborative brand positioning analysis of leading industry players (shortlisted on the basis of revenues generated in 2021), highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as number of services offered and device class.

Chapter 10 presents a detailed analysis of completed, ongoing, and planned clinical studies focused on medical devices, based on several relevant parameters, such as trial registration year, trial phase, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), target therapeutic area(s) and key geographical regions.

Chapter 11 features a detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2022 (till March). It is worth mentioning that the data captured during our research was analysed based on multiple parameters, such as year, type of agreements and geographical location of the companies.

Chapter 12 detailed analysis of the total cost of ownership for a medical device contract research service provider. It features an informed estimate of direct and indirect expenses taking into consideration 19 relevant parameters, over a span of 20 years.

Chapter 13 presents insights from the survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract research services to medical device developers.

Chapter 14 presents an insightful market forecast analysis, highlighting the likely growth of the medical devices contract research market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] target therapeutic area (Cardiovascular disorders, CNS disorders, Metabolic disorders, Oncological disorders, Ophthalmological disorders, Orthopedic disorders, Pain disorders, Psychological disorders, Respiratory disorders, and Others), [B] scale of operation (clinical and preclinical), [C] device class (class I, class II and class III), [D] types of clinical services offered (clinical trial management, consulting, data management, regulatory affairs management and others) [E] types of preclinical services offered (material characterization and analytical services, biocompatibility testing, sterility and microbiology testing and others), and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). 

Chapter 15 provides a discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

Chapter 16 presents a discussion on the upcoming opportunities / trends of medical device contract services market that are likely to impact the future evolution of this domain over the coming years. These include (but not limited to) growth in number of connected devices, adoption of data analytics and real-time monitoring solutions, growing need for cloud-based computing and storage solutions and growing demands for real-world evidence to obtain regulatory approval. 

Chapter 17 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interview held with Lajos Sarosi (Chief Executive Officer and Co-founder, HungaroTrial), Lee King (Senior Vice President, Business Development and Marketing), Christopher Rupp (Vice President of Global Marketing and Commercial Operations, NAMSA), Claus Hemiker (Head, Business Development), Christian Wolflehner (General Manager, CW Research & Management), Troy Mccall (Chief Operating Officer, CROMSOURCE), Nazish Urooj (Senior Manager, Medical & Clinical Operations, Metrics Research), C. Omprakash (Technical Director and Partner, Vyomus Consulting), Tania Persson (Director of Business Development, A+ Science) and Alexa Foltin-Mertgen (Business Development Manager, AtoZ-CRO).

Chapter 18 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Medical Devices
3.2.1. Historical Evolution of Medical Devices
3.2.2. Classification of Medical Devices
3.3. Overview of Contract Research Organizations (CROs)
3.3.1. Evolution of CROs
3.4. Role of CROs in the Medical Device Industry

3.5. Types of Medical Device CROs
3.6. Types of Services Offered by CROs
3.7. Advantages of Outsourcing Operations to CROs
3.8. Risks and Challenges Associated with Outsourcing
3.9. Key Considerations WhileSelecting a Suitable CRO Partner

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Medical Device CROs: Clinical Service Providers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Area of Specialization
4.2.6. Analysis by Device Class
4.2.7. Analysis by Type of Clinical Operation Service Offered
4.2.8. Analysis by Type of Regulatory Affairs-related Service Offered
4.2.9. Analysis by Type of Additional Service Offered
4.2.10. Analysis by Medical Device Regulatory Compliance Authority

4.3. Medical Device CROs: Preclinical Service Providers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Analysis by Type of Preclinical Service Offered

4.4. Medical Device CROs: Standalone Service Providers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Company Size and Location of Headquarters

5. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
5.1. Chapter Overview
5.2. General Regulatory and Reimbursement Guidelines for Medical Devices

5.3. Regulatory and Reimbursement Landscape in North America
5.3.1. The US Scenario
5.3.1.1. Regulatory Authority
5.3.1.2. Review / Approval Process
5.3.1.3. Reimbursement Landscape
5.3.1.3.1. Payer Mix
5.3.1.3.2. Reimbursement Process

5.3.2. The Canadian Scenario
5.3.2.1. Regulatory Authority
5.3.2.2. Review / Approval Process
5.3.2.3. Reimbursement Landscape
5.3.2.3.1. Payer Mix
5.3.2.3.2. Reimbursement Process

5.3.3. The Mexican Scenario
5.3.3.1. Regulatory Authority
5.3.3.2. Review / Approval Process
5.3.3.3. Reimbursement Landscape
5.3.3.3.1. Payer Mix

5.4. Regulatory and Reimbursement Landscape in Europe
5.4.1. Overall Scenario
5.4.1.1. Overview of Regulatory Authorities
5.4.1.2. Overall Review / Approval Process

5.4.2. The UK Scenario
5.4.2.1. Regulatory Authority
5.4.2.2. Review / Approval Process
5.4.2.3. Reimbursement Landscape
5.4.2.3.1. Payer Mix
5.4.2.3.2. Reimbursement Process

5.4.3. The French Scenario
5.4.3.1. Regulatory Authority
5.4.3.2. Review / Approval Process
5.4.3.3. Reimbursement Landscape
5.4.3.3.1. Payer Mix
5.4.3.3.2. Reimbursement Process

5.4.4. The German Scenario
5.4.4.1. Regulatory Authority
5.4.4.2. Review / Approval Process
5.4.4.3. Reimbursement Landscape
5.4.4.3.1. Payer Mix
5.4.4.3.2. Reimbursement Process

5.4.5. The Italian Scenario
5.4.5.1. Regulatory Authority
5.4.5.2. Review / Approval Process
5.4.5.3. Reimbursement Landscape
5.4.5.3.1. Payer Mix
5.4.5.3.2. Reimbursement Process

5.4.6. The Spanish Scenario
5.4.6.1. Regulatory Authority
5.4.6.2. Review / Approval Process
5.4.6.3. Reimbursement Landscape
5.4.6.3.1. Payer Mix
5.4.6.3.2. Reimbursement Process

5.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
5.5.1. The Australian Scenario
5.5.1.1. Regulatory Authority
5.5.1.2. Review / Approval Process
5.5.1.3. Reimbursement Landscape
5.5.1.3.1. Payer Mix
5.5.1.3.2. Reimbursement Process

5.5.2. The Brazilian Scenario
5.5.2.1. Regulatory Authority
5.5.2.2. Review / Approval Process
5.5.2.3. Reimbursement Landscape
5.5.2.3.1. Payer Mix
5.5.2.3.2. Reimbursement Process

5.5.3. The Chinese Scenario
5.5.3.1. Regulatory Authority
5.5.3.2. Review / Approval Process
5.5.3.3. Reimbursement Landscape
5.5.3.3.1. Payer Mix
5.5.3.3.2. Reimbursement Process

5.5.4. The Indian Scenario
5.5.4.1. Regulatory Authority
5.5.4.2. Review / Approval Process
5.5.4.3. Reimbursement Landscape
5.5.4.3.1. Payer Mix

5.5.5. The Israeli Scenario
5.5.5.1. Regulatory Authority
5.5.5.2. Review / Approval Process
5.5.5.3. Reimbursement Landscape
5.5.5.3.1. Payer Mix

5.5.6. The Japanese Scenario
5.5.6.1. Regulatory Authority
5.5.6.2. Review / Approval Process
5.5.6.3. Reimbursement Landscape
5.5.6.3.1. Payer Mix
5.5.6.3.2. Reimbursement Process

5.5.7. The New Zealand Scenario
5.5.7.1. Regulatory Authority
5.5.7.2. Review / Approval Process
5.5.7.3. Reimbursement Landscape
5.5.7.3.1. Payer Mix
5.5.7.3.2. Reimbursement Process

5.5.8. The Singapore Scenario
5.5.8.1. Regulatory Authority
5.5.8.2. Review / Approval Process
5.5.8.3. Reimbursement Landscape
5.5.8.3.1. Payer Mix
5.5.8.3.2. Reimbursement Process

5.5.9. The South Korean Scenario
5.5.9.1. Regulatory Authority
5.5.9.2. Review / Approval Process
5.5.9.3. Reimbursement Landscape
5.5.9.3.1. Payer Mix
5.5.9.3.2. Reimbursement Process

5.5.10. The South African Scenario
5.5.10.1. Regulatory Authority
5.5.10.2. Review / Approval Process
5.5.10.3. Reimbursement Landscape

5.5.11. The Taiwan Scenario
5.5.11.1. Regulatory Authority
5.5.11.2. Review / Approval Process
5.5.11.3. Reimbursement Landscape
5.5.11.3.1. Payer Mix
5.5.11.3.2. Reimbursement Process

5.5.12. The Thailand Scenario
5.5.12.1. Regulatory Authority
5.5.12.2. Review / Approval Process
5.5.12.3. Reimbursement Landscape

5.6. Comparison of Regional Regulatory Control
5.7. Concluding Remarks

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Avania (Formerly known as Factory CRO)
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Charles River Laboratories
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. CROMSOURCE
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. CSSi LifeSciences
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. Eurofins Medical Device Testing
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Recent Developments and Future Outlook

6.7. IQVIA
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. Medpace
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Recent Developments and Future Outlook

6.9. NAMSA
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Qserve Group
6.10.1. Company Overview
6.10.2. Service Portfolio
6.10.3. Recent Developments and Future Outlook

6.11. WuXi AppTec
6.11.1. Company Overview
6.11.2. Service Portfolio
6.11.3. Recent Developments and Future Outlook

7. MEDICAL DEVICE DEVELOPER AND CRO RELATIONSHIPS: KEY VALUE DRIVERS AND PERFORMANCE INDICATORS
7.1. Chapter Overview
7.2. Definition and Importance of Key Performance Indicators (KPIs)
7.3. Key Considerations for Selection of KPIs
7.4. Types of KPIs
7.4.1. Financial Indicators
7.4.1.1. Most Important KPIs
7.4.1.1.1. Financial Stability
7.4.1.1.2. Cost of Services Offered
7.4.1.1.3. Comparative Analysis of Financial Indicators

7.4.1.2. Industry Perspective
7.4.1.2.1. Sponsors’ (Big Pharma) Perspective
7.4.1.2.2. Contract Service Providers’ Perspective

7.4.2. Process and Capability Indicators
7.4.2.1. Most Important KPIs
7.4.2.1.1. Proximity to Sponsor
7.4.2.1.2. Capability to Innovate / Mitigate Risk
7.4.2.1.3. Strength of Service Portfolio
7.4.2.1.4. Comparative Analysis of Process / Capability Indicators

7.4.2.2. Industry Perspective
7.4.2.2.1. Sponsors’ (Big Pharma) Perspective
7.4.2.2.2. Contract Service Providers’ Perspective

7.4.3. Market Reputation Indicators
7.4.3.1. Most Important KPIs
7.4.3.1.1. Flexibility / Adaptability
7.4.3.1.2. Time Management
7.4.3.1.3. Quality / Reliability
7.4.3.1.4. Regulatory Compliance / Track Record
7.4.3.1.5. Comparative Analysis of Market Reputation Indicators

7.4.3.2. Industry Perspective
7.4.3.2.1. Sponsors’ (Big Pharma) Perspective
7.4.3.2.2. Contract Service Providers’ Perspective

7.5. Comparison of Key Performance Indicators
7.6. Concluding Remarks

8. COMPETITIVE BENCHMARKING
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Competitive Benchmarking by Region
8.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
8.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
8.3.3. Competitive Benchmarking: Large Players based in North America (Peer Group III)
8.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
8.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
8.3.6. Competitive Benchmarking: Large Players based in Europe (Peer Group VI)
8.3.7. Competitive Benchmarking: Small Players based in Asia-Pacific (Peer Group VII)
8.3.8. Competitive Benchmarking: Mid-sized Players based in Asia-Pacific (Peer Group VIII)
8.3.9. Competitive Benchmarking: Large Players based in Asia-Pacific (Peer Group IX)
8.3.10. Competitive Benchmarking: Small Players based in RoW (Peer Group X)
8.3.11. Competitive Benchmarking: Mid-sized Players based in RoW (Peer Group XI)
8.4. Concluding Remarks

9. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Brand Positioning Matrix: Labcorp
9.4. Brand Positioning Matrix: IQVIA
9.5. Brand Positioning Matrix: Syneos Health
9.6. Brand Positioning Matrix: PPD
9.7. Brand Positioning Matrix: ICON
9.8. Brand Positioning Matrix: Charles River Laboratories
9.9. Brand Positioning Matrix: WuXi AppTec
9.10. Brand Positioning Matrix: Medpace

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Medical Devices: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Phase of Development
10.3.4. Analysis by Study Design
10.3.5. Analysis by Therapeutic Area
10.3.6. Analysis by Geography
10.3.7. Analysis by Trial Registration Year and Geography
10.3.8. Analysis by Trial Status and Geography
10.3.9. Analysis by Type of Sponsor
10.3.10. Most Active Players: Analysis by Number of Clinical Trials

10.4. Medical Devices: Analysis by Enrolled Patient Population
10.4.1. Analysis by Trial Registration Year
10.4.2. Analysis by Phase of Development
10.4.3. Analysis by Geography
10.4.4. Analysis by Trial Status and Geography

11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Merger and Acquisition Models
11.3. Medical Device CROs: Mergers and Acquisitions
11.3.1. Analysis by Year of Merger / Acquisition
11.3.2. Analysis by Type of Agreement
11.3.3. Regional Analysis
11.3.3.1. Analysis by Continent
11.3.3.2. Intercontinental and Intracontinental Deals
11.3.3.3. Analysis by Country

11.3.4. Ownership Change Matrix
11.3.5. Analysis by Type of Company
11.3.6. Analysis by Key Value Drivers
11.3.6.1. Analysis by Year of Acquisition and Key Value Drivers

12. TOTAL COST OF OWNERSHIP IN MEDICAL DEVICES CONTRACT RESEARCH ORGANIZATION
12.1. Chapter Overview
12.2. Assumptions and Methodology
12.3. Expenditures Incurred by a Medical Device Contract Research Organization
12.3.1. Capital Expenditures (CAPEX)
12.3.2. Operational Expenditures (OPEX)
12.4. Total Cost of Ownership of Medical Devices Contract Research Organizations, 2022-2042
12.5. Total Cost of Ownership of Medical Devices Contract Research Organizations: Analysis by CAPEX and OPEX Costs, 2022 and 2042
12.5.1. Total Cost of Ownership of Medical Devices Contract Research Organizations: Analysis by CAPEX Costs, 2022-2042
12.5.2. Total Cost of Ownership of Medical Devices Contract Research Organizations: Analysis by OPEX Costs, 2022-2042
12.6. Concluding Remarks

13. SURVEY INSIGHTS
13.1. Chapter Overview
13.2. Designation of Respondents
13.3. Types of Services Offered
13.4. Target Therapeutic Area
13.5. Average Number of Annual Projects
13.6. Market Opportunity

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Assumptions and Forecast Methodology

14.3. Overall Medical Device CROs Market, 2022-2035
14.3.1. Medical Device CROs Market: Analysis by Therapeutic Area, 2022, 2028 and 2035
14.3.2. Medical Device CROs Market: Analysis by Scale of Operation, 2022-2035
14.3.3. Medical Device CROs Market: Analysis by Device Class, 2022-2035
14.3.4. Medical Device CROs Market, 2022-2035: Analysis by Type of Clinical Service Offered, 2022-2035
14.3.5. Medical Device CROs Market, 2022-2035: Analysis by Type of Preclinical Service Offered, 2022-2035
14.3.6. Medical Device CROs Market: Analysis by Geography, 2022, 2028 and 2035

14.4. Medical Device CROs Market in North America, 2022-2035
14.4.1. Medical Device CROs Market in North America: Analysis by Therapeutic Area, 2022-2035
14.4.1.1. Medical Device CROs Market for CNS Disorders in North America, 2022-2035
14.4.1.2. Medical Device CROs Market for Cardiovascular Disorders in North America, 2022-2035
14.4.1.3. Medical Device CROs Market for Oncological Disorders in North America, 2022-2035
14.4.1.4. Medical Device CROs Market for Bone Disorders in North America, 2022-2035
14.4.1.5. Medical Device CROs Market for Respiratory Disorders in North America, 2022-2035
14.4.1.6. Medical Device CROs Market for Pain Management Disorders in North America, 2022-2035
14.4.1.7. Medical Device CROs Market for Ophthalmic Disorders in North America, 2022-2035
14.4.1.8. Medical Device CROs Market for Psychological Disorders in North America, 2022-2035
14.4.1.9. Medical Device CROs Market for Metabolic Disorders in North America, 2022-2035
14.4.1.10. Medical Device CROs Market for Other Disorders in North America, 2022-2035

14.4.2. Medical Device CROs Market in North America: Analysis by Device Class, 2022-2035
14.4.2.1. Medical Device CROs Market for Class I Devices in North America, 2022-2035
14.4.2.2. Medical Device CROs Market for Class II Devices in North America, 2022-2035
14.4.2.3. Medical Device CROs Market for Class III Devices in North America, 2022-2035

14.4.3. Medical Device CROs Market in North America: Analysis by Type of Clinical Service Offered, 2022-2035
14.4.3.1. Medical Device CROs Market for Clinical Trial Management Services in North America, 2022-2035
14.4.3.2. Medical Device CROs Market for Consulting Services in North America, 2022-2035
14.4.3.3. Medical Device CROs Market for Data Management Services in North America, 2022-2035
14.4.3.4. Medical Device CROs Market for Regulatory Affairs Management Services in North America, 2022-2035
14.4.3.5. Medical Device CROs Market for Other Clinical Services in North America, 2022-2035

14.4.4. Medical Device CROs Market in North America: Analysis by Type of Preclinical Service Offered, 2022-2035
14.4.4.1. Medical Device CROs Market for Material Characterization and Analytical Services in North America, 2022-2035
14.4.4.2. Medical Device CROs Market for Biocompatibility Testing Services in North America, 2022-2035
14.4.4.3. Medical Device CROs Market for Sterility and Microbiology Testing Services in North America, 2022-2035
14.4.4.4. Medical Device CROs Market for Other Preclinical Services in North America, 2022-2035

14.5. Medical Device CROs Market in Europe, 2022-2035
14.5.1. Medical Device CROs Market in Europe: Analysis by Therapeutic Area, 2022-2035
14.5.1.1. Medical Device CROs Market for CNS Disorders in Europe, 2022-2035
14.5.1.2. Medical Device CROs Market for Cardiovascular Disorders in Europe, 2022-2035
14.5.1.3. Medical Device CROs Market for Oncological Disorders in Europe, 2022-2035
14.5.1.4. Medical Device CROs Market for Bone Disorders in Europe, 2022-2035
14.5.1.5. Medical Device CROs Market for Respiratory Disorders in Europe, 2022-2035
14.5.1.6. Medical Device CROs Market for Pain Management Disorders in Europe, 2022-2035
14.5.1.7. Medical Device CROs Market for Ophthalmic Disorders in Europe, 2022-2035
14.5.1.8. Medical Device CROs Market for Psychological Disorders in Europe, 2022-2035
14.5.1.9. Medical Device CROs Market for Metabolic Disorders in Europe, 2022-2035
14.5.1.10. Medical Device CROs Market for Other Disorders in Europe, 2022-2035

14.5.2. Medical Device CROs Market in Europe: Analysis by Device Class, 2022-2035
14.5.2.1. Medical Device CROs Market for Class I Devices in Europe, 2022-2035
14.5.2.2. Medical Device CROs Market for Class II Devices in Europe, 2022-2035
14.5.2.3. Medical Device CROs Market for Class III Devices in Europe, 2022-2035

14.5.3. Medical Device CROs Market in Europe: Analysis by Type of Clinical Service Offered, 2022-2035
14.5.3.1. Medical Device CROs Market for Clinical Trial Management Services in Europe, 2022-2035
14.5.3.2. Medical Device CROs Market for Consulting Services in Europe, 2022-2035
14.5.3.3. Medical Device CROs Market for Data Management Services in Europe, 2022-2035
14.5.3.4. Medical Device CROs Market for Regulatory Affairs Management Services in Europe, 2022-2035
14.5.3.5. Medical Device CROs Market for Other Clinical Services in Europe, 2022-2035

14.5.4. Medical Device CROs Market in Europe: Analysis by Type of Preclinical Service Offered, 2022-2035
14.5.4.1. Medical Device CROs Market for Material Characterization and Analytical Services in Europe, 2022-2035
14.5.4.2. Medical Device CROs Market for Biocompatibility Testing Services in Europe, 2022-2035
14.5.4.3. Medical Device CROs Market for Sterility and Microbiology Testing Services in Europe, 2022-2035
14.5.4.4. Medical Device CROs Market for Other Preclinical Services in Europe, 2022-2035

14.6. Medical Device CROs Market in Asia-Pacific, 2022-2035
14.6.1. Medical Device CROs Market in Asia-Pacific: Analysis by Therapeutic Area, 2022-2035
14.6.1.1. Medical Device CROs Market for CNS Disorders in Asia-Pacific, 2022-2035
14.6.1.2. Medical Device CROs Market for Cardiovascular Disorders in Asia-Pacific, 2022-2035
14.6.1.3. Medical Device CROs Market for Oncological Disorders in Asia-Pacific, 2022-2035
14.6.1.4. Medical Device CROs Market for Bone Disorders in Asia-Pacific, 2022-2035
14.6.1.5. Medical Device CROs Market for Respiratory Disorders in Asia-Pacific, 2022-2035
14.6.1.6. Medical Device CROs Market for Pain Management Disorders in Asia-Pacific, 2022-2035
14.6.1.7. Medical Device CROs Market for Ophthalmic Disorders in Asia-Pacific, 2022-2035
14.6.1.8. Medical Device CROs Market for Psychological Disorders in Asia-Pacific, 2022-2035
14.6.1.9. Medical Device CROs Market for Metabolic Disorders in Asia-Pacific, 2022-2035
14.6.1.10. Medical Device CROs Market for Other Disorders in Asia-Pacific, 2022-2035

14.6.2. Medical Device CROs Market in Asia-Pacific: Analysis by Device Class, 2022-2035
14.6.2.1. Medical Device CROs Market for Class I Devices in Asia-Pacific, 2022-2035
14.6.2.2. Medical Device CROs Market for Class II Devices in Asia-Pacific, 2022-2035
14.6.2.3. Medical Device CROs Market for Class III Devices in Asia-Pacific, 2022-2035

14.6.3. Medical Device CROs Market in Asia-Pacific: Analysis by Type of Clinical Service Offered, 2022-2035
14.6.3.1. Medical Device CROs Market for Clinical Trial Management Services in Asia-Pacific, 2022-2035
14.6.3.2. Medical Device CROs Market for Consulting Services in Asia-Pacific, 2022-2035
14.6.3.3. Medical Device CROs Market for Data Management Services in Asia-Pacific, 2022-2035
14.6.3.4. Medical Device CROs Market for Regulatory Affairs Management Services in Asia-Pacific, 2022-2035
14.6.3.5. Medical Device CROs Market for Other Clinical Services in Asia-Pacific, 2022-2035

14.6.4. Medical Device CROs Market in Asia-Pacific: Analysis by Type of Preclinical Service Offered, 2022-2035
14.6.4.1. Medical Device CROs Market for Material Characterization and Analytical Services in Asia-Pacific, 2022-2035
14.6.4.2. Medical Device CROs Market for Biocompatibility Testing Services in Asia-Pacific, 2022-2035
14.6.4.3. Medical Device CROs Market for Sterility and Microbiology Testing Services in Asia-Pacific, 2022-2035
14.6.4.4. Medical Device CROs Market for Other Preclinical Services in Asia-Pacific, 2022-2035

14.7. Medical Device CROs Market in Rest of the World, 2022-2035
14.7.1. Medical Device CROs Market in Rest of the World: Analysis by Therapeutic Area, 2022-2035
14.7.1.1. Medical Device CROs Market for CNS Disorders in Rest of the World, 2022-2035
14.7.1.2. Medical Device CROs Market for Cardiovascular Disorders in Rest of the World, 2022-2035
14.7.1.3. Medical Device CROs Market for Oncological Disorders in Rest of the World, 2022-2035
14.7.1.4. Medical Device CROs Market for Bone Disorders in Rest of the World, 2022-2035
14.7.1.5. Medical Device CROs Market for Respiratory Disorders in Rest of the World, 2022-2035
14.7.1.6. Medical Device CROs Market for Pain Management Disorders in Rest of the World, 2022-2035
14.7.1.7. Medical Device CROs Market for Ophthalmic Disorders in Rest of the World, 2022-2035
14.7.1.8. Medical Device CROs Market for Psychological Disorders in Rest of the World, 2022-2035
14.7.1.9. Medical Device CROs Market for Metabolic Disorders in Rest of the World, 2022-2035
14.7.1.10. Medical Device CROs Market for Other Disorders in Rest of the World, 2022-2035

14.7.2. Medical Device CROs Market in Rest of the World: Analysis by Device Class, 2022-2035
14.7.2.1. Medical Device CROs Market for Class I Devices in Rest of the World, 2022-2035
14.7.2.2. Medical Device CROs Market for Class II Devices in Rest of the World, 2022-2035
14.7.2.3. Medical Device CROs Market for Class III Devices in Rest of the World, 2022-2035

14.7.3. Medical Device CROs Market in Rest of the World: Analysis by Type of Clinical Service Offered, 2022-2035
14.7.3.1. Medical Device CROs Market for Clinical Trial Management Services in Rest of the World, 2022-2035
14.7.3.2. Medical Device CROs Market for Consulting Services in Rest of the World, 2022-2035
14.7.3.3. Medical Device CROs Market for Data Management Services in Rest of the World, 2022-2035
14.7.3.4. Medical Device CROs Market for Regulatory Affairs Management Services in Rest of the World, 2022-2035
14.7.3.5. Medical Device CROs Market for Other Clinical Services in Rest of the World, 2022-2035

14.7.4. Medical Device CROs Market in Rest of the World: Analysis by Type of Preclinical Service Offered, 2022-2035
14.7.4.1. Medical Device CROs Market for Material Characterization and Analytical Services in Rest of the World, 2022-2035
14.7.4.2. Medical Device CROs Market for Biocompatibility Testing Services in Rest of the World, 2022-2035
14.7.4.3. Medical Device CROs Market for Sterility and Microbiology Testing Services in Rest of the World, 2022-2035
14.7.4.4. Medical Device CROs Market for Other Preclinical Services in Rest of the World, 2022-2035

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Concluding Remarks

16. FUTURE TRENDS AND OPPORTUNITIES
16.1. Chapter Overview
16.2. Anticipated Growth in Number of Connected Devices
16.3. Adoption of Data Analytics and Real-Time Monitoring Solutions
16.4. Need for Cloud-based Computing and Storage Solutions
16.5. Growing Demand for Real World Evidence to Obtain Regulatory Approval
16.6. Concluding Remarks

17. INTERVIEW TRANSCRIPTS
17.1. Chapter Overview
17.2. HungaroTrial
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Lajos Sarosi, Chief Executive Officer and Co-founder
17.3. ClinChoice
17.3.1. Company Snapshot
17.3.2. Lee King, Senior Vice President of Business Development and Marketing
17.4. NAMSA
17.4.1. Company Snapshot
17.4.2. Christopher Rupp, Vice President of Global Marketing and Commercial Operations
17.5. CTC North
17.5.1. Company Snapshot
17.5.2. Claus Hemiker, Head of Business Development
17.6. CW Research & Management
17.6.1. Company Snapshot
17.6.2. Christian Wolflehner, General Manager
17.7. CROMSOURCE
17.7.1. Company Snapshot
17.7.2. Troy McCall, Chief Operating Officer
17.8. Metrics Research
17.8.1. Company Snapshot
17.8.2. Nazish Urooj, Senior manager, Medical & Clinical Operations
17.9. Vyomus Consulting
17.9.1. Company Snapshot
17.9.2. C. Omprakash, Technical Director and Partner
17.10. A+ Science
17.10.1. Company Snapshot
17.10.2. Tania Persson, Director of Business Development
17.11. AtoZ-CRO
17.11.1 Company Snapshot
17.11.2. Alexa Foltin-Mertgen, Business Development Manager

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Mergers and Acquisitions
Figure 2.4 Executive Summary: Total Cost of Ownership
Figure 2.5 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Historical Timeline of Medical Device Inventions
Figure 3.2 Medical Device: Development Process and Timeline
Figure 3.3 Types of CROs Engaged in the Medical Device Market
Figure 3.4 Services Offered by CROs
Figure 3.5 Risks / Challenges Associated with Outsourcing Operations to CROs
Figure 4.1 Medical Device Clinical CROs: Distribution by Year of Establishment
Figure 4.2 Medical Device Clinical CROs: Distribution by Company Size
Figure 4.3 Medical Device Clinical CROs: Distribution by Location of Headquarters
Figure 4.4 Medical Device Clinical CROs: Distribution by Company Size and Location of Headquarters
Figure 4.5 Medical Device Clinical CROs: Distribution by Area of Specialization
Figure 4.6 Medical Device Clinical CROs: Distribution by Device Class
Figure 4.7 Medical Device Clinical CROs: Distribution by Type of Clinical Operation Service Offered
Figure 4.8 Medical Device Clinical CROs: Distribution by Year of Establishment, Type of Clinical Service Offered and Geography
Figure 4.9 Medical Device Clinical CROs: Distribution by Type of Regulatory Affairs-related Service Offered
Figure 4.10 Medical Device Clinical CROs: Distribution by Type of Additional Service Offered
Figure 4.11 Medical Device Clinical CROs: Distribution by Type of Medical Device Regulatory Compliance Authority
Figure 4.12 Medical Device Preclinical CROs: Distribution by Year of Establishment
Figure 4.13 Medical Device Preclinical CROs: Distribution by Company Size
Figure 4.14 Medical Device Preclinical CROs: Distribution by Location of Headquarters
Figure 4.15 Medical Device Preclinical CROs: Distribution by Company Size and Location of Headquarters
Figure 4.16 Medical Device Preclinical CROs: Distribution by Type of Preclinical Service Offered
Figure 4.17 Medical Device Preclinical CROs: Distribution by Year of Establishment, Type of Preclinical Service Offered and Geography
Figure 4.18 Medical Device Standalone CROs: Distribution by Year of Establishment
Figure 4.19 Medical Device Standalone CROs: Distribution by Company Size
Figure 4.20 Medical Device Standalone CROs: Distribution by Location of Headquarters
Figure 4.21 Medical Device Standalone CROs: Distribution by Company Size and Location of Headquarters
Figure 5.1 Key Regulatory Authorities for Medical Devices
Figure 5.2 Medical Devices Review / Approval Process in the US
Figure 5.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 5.4 Medical Devices National Coverage Determination Process in the US
Figure 5.5 Medical Devices Review / Approval Process in Canada
Figure 5.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 5.7 Medical Devices Review / Approval Process in Mexico
Figure 5.8 Regulatory Bodies in EU5 Countries
Figure 5.9 Steps involved in CE Marking Process
Figure 5.10 Medical Devices Review / Approval Process in Europe
Figure 5.11 Medical Devices Review / Approval Process in the UK
Figure 5.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 5.13 Reimbursement Process for Medical Devices in the UK
Figure 5.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 5.15 Reimbursement Process for Medical Devices through List of Products and Services Qualifying for Reimbursement
Figure 5.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 5.17 Reimbursement Process for In-Patient Setting in Germany
Figure 5.18 Reimbursement Process for Out-Patient Care in Germany
Figure 5.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Figure 5.20 Reimbursement Process for Medical Devices in Italy
Figure 5.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 5.22 Reimbursement Process for Medical Devices in Spain
Figure 5.23 Medical Devices Review / Approval Process in Australia
Figure 5.24 Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Figure 5.25 Medical Devices Review / Approval Process in Brazil
Figure 5.26 Reimbursement Process for Medical Devices in Brazil
Figure 5.27 Medical Devices Review / Approval Process in China
Figure 5.28 Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Figure 5.29 Reimbursement Approval Process for Medical Devices in Shanghai
Figure 5.30 Medical Devices Review / Approval Process in India
Figure 5.31 Healthcare Insurance Coverage in Israel: Distribution by Type of Coverage
Figure 5.32 Medical Devices Review / Approval Process in Japan
Figure 5.33 Snapshot of the Regulatory and Reimbursement Process in Japan
Figure 5.34 Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Figure 5.35 Reimbursement Process for New Medical Devices in Japan
Figure 5.36 Medical Devices Review / Approval Process in New Zealand
Figure 5.37 Healthcare Insurance Coverage in New Zealand: Distribution by Type of Coverage
Figure 5.38 Medical Devices Review / Approval Process in Singapore
Figure 5.39 Medical Devices Review / Approval Process in South Korea
Figure 5.40 Healthcare Insurance Coverage in South Korea: Distribution by Type of Coverage
Figure 5.41 Medical Devices Review / Approval Process in South Africa
Figure 5.42 Medical Devices Review / Approval Process in Taiwan
Figure 5.43 Healthcare Insurance Coverage in Taiwan: Distribution by Type of Coverage
Figure 5.44 Medical Devices Review / Approval Process in Thailand
Figure 5.45 Heat Map Analysis: Comparison of Regional Regulatory Control for Medical Devices
Figure 5.46 Regulatory Control for Medical Devices: Regional Distribution by Device Risk Category
Figure 6.1 Avania: Service Portfolio
Figure 6.2 Charles River Laboratories: Service Portfolio
Figure 6.3 CROMSOURCE: Service Portfolio
Figure 6.4 CSSi LifeSciences: Service Portfolio
Figure 6.5 Eurofins Medical Device Testing: Preclinical Service Portfolio
Figure 6.6 Eurofins Medical Device Testing: Clinical Service Portfolio
Figure 6.7 IQVIA: Service Portfolio
Figure 6.8 Medpace: Service Portfolio
Figure 6.9 NAMSA: Service Portfolio
Figure 6.10 Qserve Group: Service Portfolio
Figure 6.11 WuXi AppTec: Preclinical Service Portfolio
Figure 6.12 WuXi AppTec: Clinical Service Portfolio
Figure 7.1 Key Attributes for Selection of Key Performance Indicators (KPIs)
Figure 7.2 Types of KPIs
Figure 7.3 Financial Indicators: Comparative Analysis of KPIs considered by Big Pharma Companies
Figure 7.4 Financial Indicators: Sponsors’ (Big Pharma) Perspective
Figure 7.5 Financial Indicators: Contract Service Providers’ Perspective
Figure 7.6 Process / Capability Indicators: Comparative Analysis of KPIs considered by Big Pharma Companies
Figure 7.7 Process / Capability Indicators: Sponsors’ (Big Pharma) Perspective
Figure 7.8 Process / Capability Indicators: Contract Service Providers’ Perspective
Figure 7.9 Market Reputation Indicators: Comparative Analysis of KPIs considered by Big Pharma Companies
Figure 7.10 Market Reputation Indicators: Sponsors’ (Big Pharma) Perspective
Figure 7.11 Market Reputation Indicators: Contract Service Providers’ Perspective
Figure 7.12 Comparison of Key Factors to be considered while selecting KPIs for Medical Devices
Figure 8.1 Competitive Benchmarking: Distribution by Region and Company Size
Figure 8.2 Competitive Benchmarking: Small Players based in North America (Peer Group I)
Figure 8.3 Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
Figure 8.4 Competitive Benchmarking: Large Players based in North America (Peer Group III)
Figure 8.5 Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
Figure 8.6 Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
Figure 8.7 Competitive Benchmarking: Large Players based in Europe (Peer Group VI)
Figure 8.8 Competitive Benchmarking: Small Players based in Asia-Pacific (Peer Group VII)
Figure 8.9 Competitive Benchmarking: Mid-sized Players based in Asia-Pacific (Peer Group VIII)
Figure 8.10 Competitive Benchmarking: Large Players based in Asia-Pacific (Peer Group IX)
Figure 8.11 Competitive Benchmarking: Small Players based in Rest of the World (Peer Group X)
Figure 8.12 Competitive Benchmarking: Mid-sized Players based in Rest of the World (Peer Group XI)
Figure 8.13 Competitive Benchmarking Summary
Figure 9.1 Brand Positioning of Key Industry Players: Unfair Advantage
Figure 9.2 Brand Positioning of Key Industry Players: Reasons to Believe
Figure 9.3 Brand Positioning Matrix: Labcorp
Figure 9.4 Brand Positioning Matrix: IQVIA
Figure 9.5 Brand Positioning Matrix: Syneos Health
Figure 9.6 Brand Positioning Matrix: PPD
Figure 9.7 Brand Positioning Matrix: ICON
Figure 9.8 Brand Positioning Matrix: Charles River Laboratories
Figure 9.9 Brand Positioning Matrix: WuXi AppTec
Figure 9.10 Brand Positioning Matrix: Medpace
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, 2015-2022
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Phase of Development
Figure 10.4 Clinical Trial Analysis: Distribution by Study Design
Figure 10.5 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.6 Clinical Trial Analysis: Distribution by Geography
Figure 10.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 10.8 Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 10.9 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 10.10 Most Active Players: Distribution by Number of Clinical Trials
Figure 10.11 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 10.12 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Phase of Development
Figure 10.13 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 10.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 11.1 Mergers and Acquisitions: Cumulative Year-Wise Trend (2015-2022)
Figure 11.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 11.3 Mergers and Acquisitions: Distribution by Year and Type of Agreement
Figure 11.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 11.5 Mergers and Acquisitions: Intercontinental and Intracontinental Acquisitions
Figure 11.6 Mergers and Acquisitions: Country-wise Distribution
Figure 11.7 Mergers and Acquisitions: Ownership Change Matrix
Figure 11.8 Mergers and Acquisitions: Distribution by Type of Company
Figure 11.9 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 11.10 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 12.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 12.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 12.3 Total Cost of Ownership of Medical Devices Contract Research Organizations, 2022-2042 (USD Million)
Figure 12.4 Total Cost of Ownership of Medical Devices Contract Research Organizations: Distribution by CAPEX and OPEX Costs, 2022 and 2042 (USD Million)
Figure 12.5 Total Cost of Ownership of Medical Devices Contract Research Organizations: Distribution by CAPEX Costs, 2022-2042 (USD Million)
Figure 12.6 Total Cost of Ownership of Medical Devices Contract Research Organizations: Distribution by OPEX Costs, 2022-2042 (USD Million)
Figure 13.1 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Figure 13.2 Survey Insights: Distribution of Respondents by Type of Service Offered
Figure 13.3 Survey Insights: Distribution of Respondents by Therapeutic Area
Figure 13.4 Survey Insights: Distribution of Respondents by Average Number of Annual Projects
Figure 13.5 Survey Insights: Distribution of Respondents by Market Opportunity
Figure 14.1 Overall Medical Device CROs Market, 2022-2035 (USD Billion)
Figure 14.2 Medical Device CROs Market, 2022, 2028 and 2035: Distribution by Therapeutic Area (USD Billion)
Figure 14.3 Medical Device CROs Market, 2022-2035: Distribution by Scale of Operation (USD Billion)
Figure 14.4 Medical Device CROs Market, 2022-2035: Distribution by Device Class (USD Billion)
Figure 14.5 Medical Device CROs Market, 2022-2035: Distribution by Type of Clinical Service Offered (USD Billion)
Figure 14.6 Medical Device CROs Market, 2022-2035: Distribution by Type of Preclinical Service Offered (USD Billion)
Figure 14.7 Medical Device CROs Market, 2022, 2028 and 2035: Distribution by Geography (USD Billion)
Figure 14.8 Medical Device CROs Market in North America, 2022-2035 (USD Billion)
Figure 14.9 Medical Device CROs Market for CNS Disorders in North America, 2022-2035 (USD Billion)
Figure 14.10 Medical Device CROs Market for Cardiovascular Disorders in North America, 2022-2035 (USD Billion)
Figure 14.11 Medical Device CROs Market for Oncological Disorders in North America, 2022-2035 (USD Billion)
Figure 14.12 Medical Device CROs Market for Bone Disorders in North America, 2022-2035 (USD Billion)
Figure 14.13 Medical Device CROs Market for Respiratory Disorders in North America, 2022-2035 (USD Billion)
Figure 14.14 Medical Device CROs Market for Pain Disorders in North America, 2022-2035 (USD Billion)
Figure 14.15 Medical Device CROs Market for Ophthalmic Disorders in North America, 2022-2035 (USD Billion)
Figure 14.16 Medical Device CROs Market for Psychological Disorders in North America, 2022-2035 (USD Billion)
Figure 14.17 Medical Device CROs Market for Metabolic Disorders in North America, 2022-2035 (USD Billion)
Figure 14.18 Medical Device CROs Market for Other Disorders in North America, 2022-2035 (USD Billion)
Figure 14.19 Medical Device CROs Market for Class I Devices in North America, 2022-2035 (USD Billion)
Figure 14.20 Medical Device CROs Market for Class II Devices in North America, 2022-2035 (USD Billion)
Figure 14.21 Medical Device CROs Market for Class III Devices in North America, 2022-2035 (USD Billion)
Figure 14.22 Medical Device CROs Market for Clinical Trial Management Services in North America, 2022-2035 (USD Billion)
Figure 14.23 Medical Device CROs Market for Consulting Services in North America, 2022-2035 (USD Billion)
Figure 14.24 Medical Device CROs Market for Data Management Services in North America, 2022-2035 (USD Billion)
Figure 14.25 Medical Device CROs Market for Regulatory Affairs Management Services in North America, 2022-2035 (USD Billion)
Figure 14.26 Medical Device CROs Market for Other Clinical Services in North America, 2022-2035 (USD Billion)
Figure 14.27 Medical Device CROs Market for Material Characterization and Analytical Services in North America, 2022-2035 (USD Billion)
Figure 14.28 Medical Device CROs Market for Biocompatibility Testing Services in North America, 2022-2035 (USD Billion)
Figure 14.29 Medical Device CROs Market for Sterility and Microbiology Testing Services in North America, 2022-2035 (USD Billion)
Figure 14.30 Medical Device CROs Market for Other Preclinical Services in North America, 2022-2035 (USD Billion)
Figure 14.31 Medical Device CROs Market in Europe, 2022-2035 (USD Billion)
Figure 14.32 Medical Device CROs Market for CNS Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.33 Medical Device CROs Market for Cardiovascular Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.34 Medical Device CROs Market for Oncological Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.35 Medical Device CROs Market for Bone Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.36 Medical Device CROs Market for Respiratory Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.37 Medical Device CROs Market for Pain Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.38 Medical Device CROs Market for Ophthalmic Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.39 Medical Device CROs Market for Psychological Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.40 Medical Device CROs Market for Metabolic Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.41 Medical Device CROs Market for Other Disorders in Europe, 2022-2035 (USD Billion)
Figure 14.42 Medical Device CROs Market for Class I Devices in Europe, 2022-2035 (USD Billion)
Figure 14.43 Medical Device CROs Market for Class II Devices in Europe, 2022-2035 (USD Billion)
Figure 14.44 Medical Device CROs Market for Class III Devices in Europe, 2022-2035 (USD Billion)
Figure 14.45 Medical Device CROs Market for Clinical Trial Management Services in Europe, 2022-2035 (USD Billion)
Figure 14.46 Medical Device CROs Market for Consulting Services in Europe, 2022-2035 (USD Billion)
Figure 14.47 Medical Device CROs Market for Data Management Services in Europe, 2022-2035 (USD Billion)
Figure 14.48 Medical Device CROs Market for Regulatory Affairs Management Services in Europe, 2022-2035 (USD Billion)
Figure 14.49 Medical Device CROs Market for Other Clinical Services in Europe, 2022-2035 (USD Billion)
Figure 14.50 Medical Device CROs Market for Material Characterization and Analytical Services in Europe, 2022-2035 (USD Billion)
Figure 14.51 Medical Device CROs Market for Biocompatibility Testing Services in Europe, 2022-2035 (USD Billion)
Figure 14.52 Medical Device CROs Market for Sterility and Microbiology Testing Services in Europe, 2022-2035 (USD Billion)
Figure 14.53 Medical Device CROs Market for Other Preclinical Services in Europe, 2022-2035 (USD Billion)
Figure 14.54 Medical Device CROs Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.55 Medical Device CROs Market for CNS Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.56 Medical Device CROs Market for Cardiovascular Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.57 Medical Device CROs Market for Oncological Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.58 Medical Device CROs Market for Bone Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.59 Medical Device CROs Market for Respiratory Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.60 Medical Device CROs Market for Pain Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.61 Medical Device CROs Market for Ophthalmic Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.62 Medical Device CROs Market for Psychological Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.63 Medical Device CROs Market for Metabolic Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.64 Medical Device CROs Market for Other Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.65 Medical Device CROs Market for Class I Devices in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.66 Medical Device CROs Market for Class II Devices in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.67 Medical Device CROs Market for Class III Devices in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.68 Medical Device CROs Market for Clinical Trial Management Services in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.69 Medical Device CROs Market for Consulting Services in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.70 Medical Device CROs Market for Data Management Services in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.71 Medical Device CROs Market for Regulatory Affairs Management Services in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.72 Medical Device CROs Market for Other Clinical Services in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.73 Medical Device CROs Market for Material Characterization and Analytical Services in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.74 Medical Device CROs Market for Biocompatibility Testing Services in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.75 Medical Device CROs Market for Sterility and Microbiology Testing Services in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.76 Medical Device CROs Market for Other Preclinical Services in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.77 Medical Device CROs Market in Rest of the World, 2022-2035 (USD Billion)
Figure 14.78 Medical Device CRO Market for CNS Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.79 Medical Device CROs Market for Cardiovascular Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.80 Medical Device CROs Market for Oncological Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.81 Medical Device CROs Market for Bone Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.82 Medical Device CROs Market for Respiratory Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.83 Medical Device CROs Market for Pain Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.84 Medical Device CROs Market for Ophthalmic Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.85 Medical Device CROs Market for Psychological Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.86 Medical Device CROs Market for Metabolic Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.87 Medical Device CROs Market for Other Disorders in Rest of the World, 2022-2035 (USD Billion)
Figure 14.88 Medical Device CROs Market for Class I Devices in Rest of the World, 2022-2035 (USD Billion)
Figure 14.89 Medical Device CROs Market for Class II Devices in Rest of the World, 2022-2035 (USD Billion)
Figure 14.90 Medical Device CROs Market for Class III Devices in Rest of the World, 2022-2035 (USD Billion)
Figure 14.91 Medical Device CROs Market for Clinical Trial Management Services in Rest of the World, 2022-2035 (USD Billion)
Figure 14.92 Medical Device CROs Market for Consulting Services in Rest of the World, 2022-2035 (USD Billion)
Figure 14.93 Medical Device CROs Market for Data Management Services in Rest of the World, 2022-2035 (USD Billion)
Figure 14.94 Medical Device CROs Market for Regulatory Affairs Management Services in Rest of the World, 2022-2035 (USD Billion)
Figure 14.95 Medical Device CROs Market for Other Clinical Services in Rest of the World, 2022-2035 (USD Billion)
Figure 14.96 Medical Device CROs Market for Material Characterization and Analytical Services in Rest of the World, 2022-2035 (USD Billion)
Figure 14.97 Medical Device CROs Market for Biocompatibility Testing Services in Rest of the World, 2022-2035 (USD Billion)
Figure 14.98 Medical Device CROs Market for Sterility and Microbiology Testing Services in Rest of the World, 2022-2035 (USD Billion)
Figure 14.99 Medical Device CROs Market for Other Preclinical Services in Rest of the World, 2022-2035 (USD Billion)
Figure 15.1 Medical Device CROs Market: SWOT Analysis
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Future Trends and Opportunities for Medical Device CROs

List Of Tables

Table 3.1 Comparison of Key Factors Considered by Medical Device Developers While Selecting a CRO Partner: Harvey Ball Analysis
Table 4.1 Medical Device CROs: List of Clinical Service Providers
Table 4.2 Medical Device Clinical CROs: Information on Device Class
Table 4.3 Medical Device Clinical CROs: Information on Type of Clinical Operation Service Offered
Table 4.4 Medical Device Clinical CROs: Information on Type of Regulatory Affairs-Related Service Offered
Table 4.5 Medical Device Clinical CROs: Information on Additional Service Offered
Table 4.6 Medical Device Clinical CROs: Information on Medical Device Regulatory Compliance Authorities
Table 4.7 Medical Device CROs: List of Preclinical Service Providers
Table 4.8 Medical Device Preclinical CROs: Information on Type of Preclinical Services Offered
Table 4.9 Medical Device CROs: List of Standalone Service Providers
Table 5.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 5.2 Device Classification: US
Table 5.3 Device Classification: Canada
Table 5.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
Table 5.5 Device Classification: Mexico
Table 5.6 Device Classification: Europe
Table 5.7 List of CE Directives in Europe
Table 5.8 Conformity Assessment Modules in Europe
Table 5.9 Device Classification: Australia
Table 5.10 Reimbursement and Pricing Approval Process of Medical devices in Australia
Table 5.11 Device Classification: Brazil
Table 5.12 Device Classification: China
Table 5.13 Device Classification: India
Table 5.14 Device Classification: Japan
Table 5.15 Medical Devices Reimbursement Categories
Table 5.16 Device Classification: New Zealand
Table 5.17 Device Classification: Singapore
Table 5.18 Device Classification: South Korea
Table 5.19 Device Classification: South Africa
Table 5.20 Device Classification: Thailand
Table 5.21 Medical Devices Regulatory Landscape Summary
Table 5.22 Medical Devices Reimbursement Landscape Summary
Table 6.1 Avania: Company Overview
Table 6.2 Avania: Recent Developments and Future Outlook
Table 6.3 Charles River Laboratories: Company Overview
Table 6.4 Charles River Laboratories: Recent Developments and Future Outlook
Table 6.5 CROMSOURCE: Company Overview
Table 6.6 CROMSOURCE: Recent Development and Future Outlook
Table 6.7 CSSi LifeSciences: Company Overview
Table 6.8 Eurofins Medical Device Testing: Company Overview
Table 6.9 Eurofins Medical Device Testing: Recent Development and Future Outlook
Table 6.10 IQVIA: Company Overview
Table 6.11 IQVIA: Recent Development and Future Outlook
Table 6.12 Medpace: Company Overview
Table 6.13 Medpace: Recent Development and Future Outlook
Table 6.14 NAMSA: Company Overview
Table 6.15 NAMSA: Recent Development and Future Outlook
Table 6.16 Qserve Group: Company Overview
Table 6.17 Qserve Group: Recent Development and Future Outlook
Table 6.18 WuXi AppTec: Company Overview
Table 6.19 WuXi AppTec: Recent Development and Future Outlook
Table 8.1 Competitive Benchmarking Analysis: Peer Groups Definitions and Inclusions
Table 11.1 Medical Device CRO Market: List of Mergers and Acquisitions, 2015-2022
Table 11.2 Acquisitions: Key Value Drivers
Table 13.1 Survey Insights: Overview of Respondents
Table 13.2 Survey Insights: Designation and Seniority Level of Respondents
Table 13.3 Survey Insights: Information on Type of Service Offered
Table 13.4 Survey Insights: Information on Target Therapeutic Area
Table 13.5 Survey Insights: Information on Average Number of Projects
Table 13.6 Survey Insights: Information on Market Opportunity
Table 14.1 Key Assumptions
Table 18.1 Medical Device Clinical CROs: Distribution by Year of Establishment
Table 18.2 Medical Device Clinical CROs: Distribution by Company Size
Table 18.3 Medical Device Clinical CROs: Distribution by Location of Headquarters
Table 18.4 Medical Device Clinical CROs: Distribution by Company Size and Location of Headquarters
Table 18.5 Medical Device Clinical CROs: Distribution by Area of Specialization
Table 18.6 Medical Device Clinical CROs: Distribution by Device Class
Table 18.7 Medical Device Clinical CROs: Distribution by Type of Clinical Operation Services Offered
Table 18.8 Medical Device Clinical CROs: Distribution by Distribution by Year of Establishment, Type of Clinical Services Offered, and Geography
Table 18.9 Medical Device Clinical CROs: Distribution by Type of Regulatory Affairs Related Services Offered
Table 18.10 Medical Device Clinical CROs: Distribution by Type of Additional Services Offered
Table 18.11 Medical Device Clinical CROs: Distribution by Type of Medical Device Regulatory Compliance Authorities
Table 18.12 Medical Device Preclinical CROs: Distribution by Year of Establishment
Table 18.13 Medical Device Preclinical CROs: Distribution by Company Size
Table 18.14 Medical Device Preclinical CROs: Distribution by Location of Headquarters
Table 18.15 Medical Device Preclinical CROs: Distribution by Company Size and Location of Headquarters
Table 18.16 Medical Device Preclinical CROs: Distribution by Type of Preclinical Services Offered
Table 18.17 Medical Device Preclinical CROs: Distribution by Year of Establishment, Type of Preclinical Services Offered, and Geography
Table 18.18 Medical Device Standalone CROs: Distribution by Year of Establishment
Table 18.19 Medical Device Standalone CROs: Distribution by Company Size
Table 18.20 Medical Device Standalone CROs: Distribution by Location of Headquarters
Table 18.21 Medical Device Standalone CROs: Distribution by Company Size and Location of Headquarters
Table 18.22 Competitive Benchmarking: Distribution by Region and Company Size
Table 18.23 Competitive Benchmarking: Small Players based in North America (Peer Group I)
Table 18.24 Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
Table 18.25 Competitive Benchmarking: Large Players based in North America (Peer Group III)
Table 18.26 Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
Table 18.27 Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
Table 18.28 Competitive Benchmarking: Large Players based in Europe (Peer Group VI)
Table 18.29 Competitive Benchmarking: Small Players based in Asia-Pacific (Peer Group VII)
Table 18.30 Competitive Benchmarking: Mid-sized Players based in Asia-Pacific (Peer Group VIII)
Table 18.31 Competitive Benchmarking: Large Players based in Asia-Pacific (Peer Group IX)
Table 18.32 Competitive Benchmarking: Small Players based in Rest of the World (Peer Group X)
Table 18.33 Competitive Benchmarking: Mid-sized Players based in Rest of the World (Peer Group XI)
Table 18.34 Brand Positioning of Key Industry Players: Unfair Advantage
Table 18.35 Brand Positioning of Key Industry Players: Reasons to Believe
Table 18.36 Brand Positioning Matrix: Labcorp
Table 18.37 Brand Positioning Matrix: IQVIA
Table 18.38 Brand Positioning Matrix: Syneos Health
Table 18.39 Brand Positioning Matrix: PPD
Table 18.40 Brand Positioning Matrix: ICON
Table 18.41 Brand Positioning Matrix: Charles River Laboratories
Table 18.42 Brand Positioning Matrix: WuXi AppTec
Table 18.43 Brand Positioning Matrix: Medpace
Table 18.44 Clinical Trial Analysis: Distribution by Trial Registration Year, 2015-2022
Table 18.45 Clinical Trial Analysis: Distribution by Trial Status
Table 18.46 Clinical Trial Analysis: Distribution by Phase of Development
Table 18.47 Clinical Trial Analysis: Distribution by Study Design
Table 18.48 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 18.49 Clinical Trial Analysis: Distribution by Geography
Table 18.50 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Table 18.51 Clinical Trial Analysis: Distribution by Trial Status and Geography
Table 18.52 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 18.53 Most Active Players: Distribution by Number of clinical Trials
Table 18.54 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 18.55 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Phase of Development
Table 18.56 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 18.57 Clinical Trial Analysis: Distribution of Enrolled Patient Population Trial Status and Geography
Table 18.58 Mergers and Acquisitions: Cumulative Year-Wise Trend (2015-2022)
Table 18.59 Mergers and Acquisitions: Distribution by Type of Agreement
Table 18.60 Mergers and Acquisitions: Distribution by Year and Type of Agreement
Table 18.61 Mergers and Acquisitions: Continent-wise Distribution
Table 18.62 Mergers and Acquisitions: Intercontinental and Intracontinental Acquisitions
Table 18.63 Mergers and Acquisitions: Country-wise Distribution
Table 18.64 Mergers and Acquisitions: Ownership Change Matrix
Table 18.65 Mergers and Acquisitions: Distribution by Type of Company
Table 18.66 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 18.67 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
Table 18.68 Total Cost of Ownership: Capital Expenditures (CAPEX)
Table 18.69 Total Cost of Ownership: Operational Expenditures (OPEX)
Table 18.70 Total Cost of ownership in Medical Devices Contract Research Organization, 2022-2042 (USD Million)
Table 18.71 Total Cost of Ownership of Medical Devices Contract Research Organization: Distribution by CAPEX and OPEX, 2022 and 2042 (USD Million)
Table 18.72 Total Cost of Ownership in Medical Devices Contract Research Organization, 2022: Distribution by CAPEX (USD Million)
Table 18.73 Total Cost of Ownership in Medical Devices Contract Research Organization, 2022-2042: Distribution by OPEX (USD Million)
Table 18.74 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Table 18.75 Survey Insights: Distribution of Respondents by Type of Service Offered
Table 18.76 Survey Insights: Distribution of Respondents by Therapeutic Area
Table 18.77 Survey Insights: Distribution of Respondents by Average Number of Projects
Table 18.78 Survey Insights: Distribution of Respondents by Market Opportunity
Table 18.79 Overall Medical Device CROs Market, 2022-2035 (USD Billion)
Table 18.80 Medical Device CROs Market, 2022, 2028 and 2035: Distribution by Therapeutic Area (USD Billion)
Table 18.81 Medical Device CROs Market, 2022-2035: Distribution by Scale of Operation (USD Billion)
Table 18.82 Medical Device CROs Market, 2022-2035: Distribution by Device Class (USD Billion)
Table 18.83 Medical Device CROs Market, 2022-2035: Distribution by Type of Clinical Service Offered (USD Billion)
Table 18.84 Medical Device CROs Market, 2022-2035: Distribution by Type of Preclinical Service Offered (USD Billion)
Table 18.85 Medical Device CROs Market, 2022, 2028 and 2035: Distribution by Geography (USD Billion)
Table 18.86 Medical Device CROs Market in North America, 2022-2035 (USD Billion)
Table 18.87 Medical Device CROs Market for CNS Disorders in North America, 2022-2035 (USD Billion)
Table 18.88 Medical Device CROs Market for Cardiovascular Disorders in North America, 2022-2035 (USD Billion)
Table 18.89 Medical Device CROs Market for Oncological Disorders in North America, 2022-2035 (USD Billion)
Table 18.90 Medical Device CROs Market for Bone Disorders in North America, 2022-2035 (USD Billion)
Table 18.91 Medical Device CROs Market for Respiratory Disorders in North America, 2022-2035 (USD Billion)
Table 18.92 Medical Device CROs Market for Pain Disorders in North America, 2022-2035 (USD Billion)
Table 18.93 Medical Device CROs Market for Ophthalmic Disorders in North America, 2022-2035 (USD Billion)
Table 18.94 Medical Device CROs Market for Psychological Disorders in North America, 2022-2035 (USD Billion)
Table 18.95 Medical Device CROs Market for Metabolic Disorders in North America, 2022-2035 (USD Billion)
Table 18.96 Medical Device CROs Market for Other Therapeutic Areas in North America, 2022-2035 (USD Billion)
Table 18.97 Medical Device CROs Market for Class I Devices in North America, 2022-2035 (USD Billion)
Table 18.98 Medical Device CROs Market for Class II Devices in North America, 2022-2035 (USD Billion)
Table 18.99 Medical Device CROs Market for Class III Devices in North America, 2022-2035 (USD Billion)
Table 18.100 Medical Device CROs Market for Clinical Trial Management Services in North America, 2022-2035 (USD Billion)
Table 18.101 Medical Device CROs Market for Consulting Services in North America, 2022-2035 (USD Billion)
Table 18.102 Medical Device CROs Market for Data Management Services in North America, 2022-2035 (USD Billion)
Table 18.103 Medical Device CROs Market for Regulatory Affairs Management Services in North America, 2022-2035 (USD Billion)
Table 18.104 Medical Device CROs Market for Other Clinical Services in North America, 2022-2035 (USD Billion)
Table 18.105 Medical Device CROs Market for Material Characterization and Analytical Services in North America, 2022-2035 (USD Billion)
Table 18.106 Medical Device CROs Market for Biocompatibility Testing Services in North America, 2022-2035 (USD Billion)
Table 18.107 Medical Device CROs Market for Sterility and Microbiology Testing Services in North America, 2022-2035 (USD Billion)
Table 18.108 Medical Device CROs Market for Other Preclinical Services in North America, 2022-2035 (USD Billion)
Table 18.109 Medical Device CROs Market in Europe, 2022-2035 (USD Billion)
Table 18.110 Medical Device CROs Market for CNS Disorders in Europe, 2022-2035 (USD Billion)
Table 18.111 Medical Device CROs Market for Cardiovascular Disorders in Europe, 2022-2035 (USD Billion)
Table 18.112 Medical Device CROs Market for Oncological Disorders in Europe, 2022-2035 (USD Billion)
Table 18.113 Medical Device CROs Market for Bone Disorders in Europe, 2022-2035 (USD Billion)
Table 18.114 Medical Device CROs Market for Respiratory Disorders in Europe, 2022-2035 (USD Billion)
Table 18.115 Medical Device CROs Market for Pain Disorders in Europe, 2022-2035 (USD Billion)
Table 18.116 Medical Device CROs Market for Ophthalmic Disorders in Europe, 2022-2035 (USD Billion)
Table 18.117 Medical Device CROs Market for Psychological Disorders in Europe, 2022-2035 (USD Billion)
Table 18.118 Medical Device CROs Market for Metabolic Disorders in Europe, 2022-2035 (USD Billion)
Table 18.119 Medical Device CROs Market for Other Therapeutic Areas in Europe, 2022-2035 (USD Billion)
Table 18.120 Medical Device CROs Market for Class I Devices in Europe, 2022-2035 (USD Billion)
Table 18.121 Medical Device CROs Market for Class II Devices in Europe, 2022-2035 (USD Billion)
Table 18.122 Medical Device CROs Market for Class III Devices in Europe, 2022-2035 (USD Billion)
Table 18.123 Medical Device CROs Market for Clinical Trial Management Services in Europe, 2022-2035 (USD Billion)
Table 18.124 Medical Device CROs Market for Consulting Services in Europe, 2022-2035 (USD Billion)
Table 18.125 Medical Device CROs Market for Data Management Services in Europe, 2022-2035 (USD Billion)
Table 18.126 Medical Device CROs Market for Regulatory Affairs Management Services in Europe, 2022-2035 (USD Billion)
Table 18.127 Medical Device CROs Market for Other Clinical Services in Europe, 2022-2035 (USD Billion)
Table 18.128 Medical Device CROs Market for Material Characterization and Analytical Services in Europe, 2022-2035 (USD Billion)
Table 18.129 Medical Device CROs Market for Biocompatibility Testing Services in Europe, 2022-2035 (USD Billion)
Table 18.130 Medical Device CROs Market for Sterility and Microbiology Testing Services in Europe, 2022-2035 (USD Billion)
Table 18.131 Medical Device CROs Market for Other Preclinical Services in Europe, 2022-2035 (USD Billion)
Table 18.132 Medical Device CROs Market in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.133 Medical Device CROs Market for CNS Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.134 Medical Device CROs Market for Cardiovascular Disorders in Asia-Pacific,2022-2035 (USD Billion)
Table 18.135 Medical Device CROs Market for Oncological Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.136 Medical Device CROs Market for Bone Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.137 Medical Device CROs Market for Respiratory Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.138 Medical Device CROs Market for Pain Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.139 Medical Device CROs Market for Ophthalmic Disorders in Asia-Pacific, 2035-2035 (USD Billion)
Table 18.140 Medical Device CROs Market for Psychological Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.141 Medical Device CROs Market for Metabolic Disorders in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.142 Medical Device CROs Market for Other Therapeutic Areas in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.143 Medical Device CROs Market for Class I Devices in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.144 Medical Device CROs Market for Class II Devices in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.145 Medical Device CROs Market for Class III Devices in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.146 Medical Device CROs Market for Clinical Trial Management Services in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.147 Medical Device CROs Market for Consulting Services in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.148 Medical Device CROs Market for Data Management Services in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.149 Medical Device CROs Market for Regulatory Affairs Management Services in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.150 Medical Device CROs Market for Other Clinical Services in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.151 Medical Device CROs Market for Material Characterization and Analytical Services in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.152 Medical Device CROs Market for Biocompatibility Testing Services in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.153 Medical Device CROs Market for Sterility and Microbiology Testing Services in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.154 Medical Device CROs Market for Other Preclinical Services in Asia-Pacific, 2022-2035 (USD Billion)
Table 18.155 Medical Device CROs Market in Rest of the World, 2022-2035 (USD Billion)
Table 18.156 Medical Device CRO Market for CNS Disorders in Rest of the World, 2022-2035 (USD Billion)
Table 18.157 Medical Device CROs Market for Cardiovascular Disorders in Rest of the World, 2022-2035 (USD Billion)
Table 18.158 Medical Device CROs Market for Oncological Disorders in Rest of the World, 2022-2035 (USD Billion)
Table 18.159 Medical Device CROs Market for Bone Disorders in Rest of the World, 2022-2035 (USD Billion)
Table 18.160 Medical Device CROs Market for Respiratory Disorders in Rest of the World, 2022-2035 (USD Billion)
Table 18.161 Medical Device CROs Market for Pain Disorders in Rest of the World, 2022-2035 (USD Billion)
Table 18.162 Medical Device CROs Market for Ophthalmic Disorders in Rest of the World, 2022-2035 (USD Billion)
Table 18.163 Medical Device CROs Market for Psychological Disorders in Rest of the World, 2022-2035 (USD Billion)
Table 18.164 Medical Device CROs Market for Metabolic Disorders in Rest of the World, 2022-2035 (USD Billion)
Table 18.165 Medical Device CROs Market for Other Therapeutic Areas in Rest of the World, 2022-2035 (USD Billion)
Table 18.166 Medical Device CROs Market for Class I Devices in Rest of the World, 2022-2035 (USD Billion)
Table 18.167 Medical Device CROs Market for Class II Devices in Rest of the World, 2022-2035 (USD Billion)
Table 18.168 Medical Device CROs Market for Class III Devices in Rest of the World, 2022-2035 (USD Billion)
Table 18.169 Medical Device CROs Market for Clinical Trial Management Services in Rest of the World, 2022-2035 (USD Billion)
Table 18.170 Medical Device CROs Market for Consulting Services in Rest of the World, 2022-2035 (USD Billion)
Table 18.171 Medical Device CROs Market for Data Management Services in Rest of the World, 2022-2035 (USD Billion)
Table 18.172 Medical Device CROs Market for Regulatory Affairs Management Services in Rest of the World, 2022-2035 (USD Billion)
Table 18.173 Medical Device CROs Market for Other Clinical Services in Rest of the World, 2022-2035 (USD Billion)
Table 18.174 Medical Device CROs Market for Material Characterization and Analytical Services in Rest of the World, 2022-2035 (USD Billion)
Table 18.175 Medical Device CROs Market for Biocompatibility Testing Services in Rest of the World, 2022-2035 (USD Billion)
Table 18.176 Medical Device CROs Market for Sterility and Microbiology Testing Services in Rest of the World, 2022-2035 (USD Billion)
Table 18.177 Medical Device CROs Market for Other Preclinical Services in Rest of the World, 2022-2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 1MED
  2. 4Clinics
  3. 4Pharma
  4. A+ Science
  5. Abiogenesis Clinpharm
  6. Abond CRO 
  7. Absorption Systems
  8. Absorption Systems 
  9. ABX-CRO
  10. Acceliant 
  11. Accell Clinical Research
  12. AccelLAB
  13. Accelovance
  14. Accredited Consultants 
  15. AccuLab Life Sciences
  16. Accuprec Research Labs
  17. Accutest Research Laboratories
  18. Acorn Regulatory
  19. Acrapack
  20. acromion
  21. aCROss Medical
  22. ACT FARMA CRO
  23. Activa Cro
  24. ADAX International
  25. Advanced Drug Development Services
  26. Advanced Medical Research
  27. Advena
  28. Affinity Bio Partners
  29. Afortiori Development
  30. Afra Pharma Consultant
  31. Aginko Research 
  32. AICROS
  33. CETERA
  34. AIX Scientifics
  35. AJW Technology Consultants
  36. ÅKRN
  37. Al Tamimi & Company
  38. Alera Labs
  39. Alira Health
  40. Allied Clinical Management
  41. Altair Clinical
  42. Altasciences
  43. Altiora 
  44. AlvaMed
  45. Amarex
  46. American Preclinical Services (Acquired by NAMSA)
  47. AmeRuss Clinical Trials
  48. Amritt 
  49. AMS
  50. Amulet Capital Partners
  51. Anagram
  52. analyze & realize
  53. Andaman Medical
  54. Anteris Medical
  55. Antrix
  56. Aperio
  57. A-Pharma
  58. A-pharmaconsult
  59. apices
  60. Appletree CI Group
  61. Applied Clinical Services
  62. Applied Healthcare Research Management
  63. Aragen Life Sciences
  64. Arazy Group Consultants
  65. Archemin
  66. Archer Research
  67. ArchiMed
  68. ARIRDMSCRO
  69. ARQon
  70. Asia Actual
  71. Asiatic Clinical Research
  72. ATLANSTAT
  73. AtoZ-CRO
  74. Auriga Research
  75. Australian Healthcare Solutions
  76. Auxilife Scientific Services
  77. Avania
  78. AVANTI
  79. AVIAD Life Sciences
  80. AXIS Clinicals
  81. Axonal-Biostatem
  82. Azelix
  83. Baláti
  84. Barons Medical Consulting
  85. Beaufort
  86. BECRO
  87. Beijing JRJ Science and Technology
  88. BIC Group
  89. BioAgile Therapeutics
  90. BioClever
  91. Biocodex 
  92. Biomapas
  93. Biomedical Regulatory Consulting
  94. BioMedical Strategy 
  95. Bioneeds
  96. BioPharma
  97. BioPlan Associates
  98. Biorasi
  99. BIOREG Services
  100. Biostat International
  101. Biotech Regulatory Solutions
  102. BioTecNiKa 
  103. BiTrial Clinical Research
  104. BLAU Pharmaceutical Service
  105. BLS laboratories
  106. Boston Biomedical Associates
  107. Boston MedTech Advisors 
  108. Brandwood CKC
  109. Bridge Pharm
  110. BRIDGE PTS
  111. Bright Pharmaceutical Services
  112. BRIGHT Research Partners
  113. BSI Life Sciences
  114. C&R Research
  115. Cactus Global
  116. Cairo University
  117. Cara Therapeutics 
  118. Cardialysis
  119. Cardinal Health
  120. CardioMed Device Consultants 
  121. Cardiovascular European Research Center (CERC)
  122. CARE Research
  123. Caritas Clinical 
  124. Carpathian Research Group
  125. CARSL Consulting 
  126. Catalyst Regulatory Services
  127. Catawba Research
  128. Cato Research
  129. CBSET
  130. CC Clinical research Consultants
  131. CCS Associates (CCSA)
  132. CERES
  133. Charles River Laboratories
  134. Chemical Inspection and Regulation Service
  135. Chiasma
  136. Chiltern
  137. China Med Device
  138. Citoxlab
  139. Clarivate Analytics 
  140. CLINACT
  141. ClinActis
  142. ClinAudits
  143. ClinChoice
  144. ClinDatrix
  145. Clinical Consulting
  146. Clinical Device Group
  147. Clinical Research & Compliance Consulting
  148. Clinical Service Center
  149. Clinical Trial Data Services
  150. CliniExperts
  151. Clinilabs Drug Development
  152. Clinipace
  153. CliniQAl™ International
  154. CliniRx
  155. Clinitude
  156. Clinius
  157. Clinlogix
  158. Clinmark
  159. Clinnex
  160. ClinPro Research
  161. Clinscience
  162. ClinSearch
  163. ClinSync
  164. Clintec, an IQVIA Company
  165. ClinVigilant
  166. Cmed
  167. CMIC Group
  168. CMX Research
  169. Cobridge
  170. Cohortias
  171. Commercial Eyes
  172. Compliance Acuity
  173. Concentrics Research
  174. CONET
  175. Consultys
  176. Convex
  177. Coronis Health
  178. Costello Medical 
  179. Courante Oncology
  180. Covance
  181. CPS Cortex
  182. CR Medicon
  183. Criterium
  184. CRO Pharmatrendz
  185. Contract Research Organization for Medical Devices & Services (CROMDS)
  186. Cromos Pharma
  187. CROMSOURCE
  188. CROS
  189. CROs NT
  190. Crown CRO
  191. CRS Clinical Research Services
  192. CSSi LifeSciences
  193. CTC North
  194. CTI
  195. CTNT
  196. CurAccel
  197. Cvigilance
  198. CW Research & Management
  199. CYA Medical Device Consulting
  200. Dalia Givony, Regulatory & Clinical Consulting
  201. Databean
  202. Datapharm Australia
  203. De Groot Technical Services
  204. DEKRA
  205. Denothex
  206. Devicia
  207. Dexcom
  208. DH RegSys
  209. dicentra
  210. DKSH Marketing Services Spain
  211. dMed
  212. Donawa Lifescience Consulting
  213. Dor Pharmaceutical Services
  214. Dove Quality Solutions
  215. DP Clinical
  216. Dr. Notghi Contract Research
  217. DreamCIS
  218. Drug Development and Regulation
  219. DSA Consultants
  220. DZS Clinical Services
  221. EAS Consulting Group
  222. East BS Clinical Research
  223. ECLEVAR MEDTECH
  224. ECSOR
  225. Edwards Lifesciences
  226. Egmont Group
  227. Element
  228. Emergent Clinical Consulting
  229. Emergo
  230. Emmes
  231. En Pointe Clinical Research
  232. Engel, Hellyer & Partners 
  233. e-novex
  234. Envigo
  235. EPIC Research
  236. EPS International
  237. EskeGen
  238. ESTERN Medical
  239. ETAP-Lab
  240. ethica CRO
  241. Ethicare Remedies
  242. EuDRAcon 
  243. Eupraxia
  244. Euraxi 
  245. Eurofins Medical Device Testing 
  246. The European Bioinformatics Institute (EMBL-EBI)
  247. Europital
  248. Everest Clinical Research
  249. Evidilya
  250. Exalon 
  251. Excelya
  252. eXcorLab
  253. Exom
  254. Experior
  255. ExperTrials
  256. Farzan Clinical Research
  257. FDAInsight
  258. FGK Clinical Research
  259. Firma Clinical Research
  260. Five Corners
  261. Focal Point Research
  262. Formac Pharmaceuticals
  263. Frestedt
  264. Freyr
  265. Gateway
  266. GCP-Service International
  267. genae
  268. Genco Medical
  269. Genelife Clinical Research
  270. GenesisCare Clinical
  271. GENOTRIX
  272. Genpact
  273. George Clinical
  274. Getz Healthcare
  275. GKM Medical Device Group
  276. Global Center for Medical Innovation 
  277. Global Pharma Tek
  278. Global Regulatory Affairs
  279. Global Regulatory Partners
  280. Global Regulatory Services 
  281. GLyPharma
  282. GlyTech
  283. GMED
  284. Greenlight Clinical
  285. Grove Group
  286. Gsap
  287. Hangzhou Tigermed Consulting
  288. Harmony Clinical Research
  289. Hart Clinical Consultants
  290. Health Decisions
  291. Healthcare International Partners
  292. HealthCore
  293. HealthLink
  294. Highthink
  295. Hilbert Paradox
  296. HingeClinica
  297. Honeywell
  298. HungaroTrial
  299. i3 Consulting 
  300. IBEX Preclinical Research
  301. ICBio 
  302. ICCR-Roßdorf 
  303. ICON
  304. ICRC-Weyer
  305. ICTA
  306. IDConic
  307. Illingworth Research Group
  308. ILS 
  309. IMARC
  310. Inamed
  311. Innomar Strategies
  312. Innovo Medical
  313. Inotiv
  314. Inrextest
  315. InSightec
  316. Integrated Resources
  317. Integrium
  318. Intellim
  319. International Drug Development Institute 
  320. International HealthCare
  321. Intertek
  322. INTOX
  323. Ipsum
  324. IQVIA
  325. Iris Pharma
  326. Ironstone Product Development 
  327. IRW
  328. ISA HEALTH
  329. Iuvo
  330. IVD Consultants
  331. IVDeology
  332. IZiel Healthcare
  333. Knipper Health
  334. Japan MDC (JMDC)
  335. JERELO
  336. Johns Hopkins University
  337. JSS Medical Research
  338. Jyton
  339. Kangan Pharmaceutical Consulting
  340. KCR
  341. KCRI
  342. KD&A
  343. Ken Block Consulting
  344. Dentons Kensington Swan 
  345. Keystone Regulatory Services
  346. KLIFO
  347. Knoell
  348. Kobridge Consulting
  349. KPS Clinical Services
  350. Krescent Medical Research
  351. L.S. Marketing & Registration
  352. L3 Healthcare
  353. LabCorp
  354. Lahav
  355. Lambda Therapeutic Research 
  356. Larix
  357. Lean RAQA
  358. Leon Research
  359. Likak Research
  360. Li-Med
  361. Linical Americas
  362. LINK Medical
  363. LIONBRIDGE
  364. Liveon Biolabs
  365. LNAge
  366. Macnair Consultants
  367. Made Consulting
  368. MakroCare
  369. Malca Chen-Zion Group
  370. MANDALA International
  371. Marti Farm
  372. Massachusetts General Hospital
  373. MasterControl
  374. MAXIS
  375. Mayo Clinic
  376. McCarthy Consultant Services
  377. MD Pharma Consulting 
  378. MD101Consulting 
  379. MD-Clinicals
  380. mdi Europa
  381. MDP-Solutions
  382. MED Institute
  383. Medanex Clinic
  384. Medelis
  385. Medfiles
  386. Medical Equipment Compliance Associates
  387. Medical Trials Analysis
  388. Mediclin Clinical Research
  389. Medicomp
  390. Mediconomics
  391. MEDICRO
  392. MedicSense
  393. Medidee
  394. MEDIKAPOLI
  395. MediqTrans
  396. MEDITRIAL
  397. MedNet
  398. Medpace
  399. MedPass International
  400. MedQ Consultants
  401. MedTech Impact Partners 
  402. MedTrials
  403. Medtronic
  404. MedVigil
  405. Medvinbio Labs
  406. Mene Research
  407. Mericon
  408. Meshayu Consultants
  409. MethodSense
  410. Metrics Research
  411. Metronomia
  412. MIC Medical
  413. Micren Healthcare
  414. Mid-Link Consulting
  415. MileStone Research
  416. MMS
  417. Mn Solutions
  418. Mobius Medical 
  419. MonitorCRO
  420. Morley Research Consortium
  421. Morula HealthTech
  422. MPI Research
  423. Mprex Healthcare
  424. Musculoskeletal Clinical Regulatory Advisers
  425. NAMSA
  426. National Cancer Institute
  427. National Institute of Mental Health
  428. Navitas Life Sciences
  429. NCGS
  430. Nelson Labs
  431. Neomed
  432. Neometrix Consulting
  433. Neopharm
  434. Neox
  435. Neozene
  436. Nerac
  437. Noble Life Sciences
  438. Northlane Capital Partners
  439. Norwich Clinical Research Associates
  440. NovaTrials
  441. Novem Healthcare
  442. Novocure
  443. Novum
  444. NoyMed
  445. NSF International
  446. Nuvisan Pharma Services
  447. Nyprax Pharma
  448. O4 Research
  449. Obelis Group
  450. Odelle Technology
  451. Onorach
  452. Opera
  453. Operon Strategist
  454. OPIS
  455. Optimal Pharm/Tox Consulting
  456. Optimal Research
  457. Optimapharm
  458. Ora
  459. Osmunda
  460. OThree Consulting
  461. Pace
  462. Pacific BioLabs
  463. Pacific Bridge Medical
  464. Pacific Clinical Research Group
  465. Pamplona Capital Management
  466. Paradigm Research
  467. PAREXEL
  468. PaxMed
  469. PCT Lab Research
  470. PDC Healthcare
  471. Peachtree BioResearch
  472. Pearl Pathways
  473. Pepgra
  474. Perfect Pharmaceuticals Consultants 
  475. Perfection-CRO
  476. Pfarrell Medical
  477. Pharma To Market
  478. Pharmaco-Kinesis
  479. Pharmahungary Group
  480. PharmaLex
  481. Pharmalog
  482. PharmaMed Research
  483. Pharmaron
  484. Pharmaseed
  485. PharmaSols
  486. Pharmaspecific
  487. PharmDedict 
  488. PharmEng Technology
  489. Pharm-Olam
  490. PharmOut
  491. Phidea Group
  492. Pilgrim Quality Solutions
  493. Pine Lake Laboratories
  494. Pivotal
  495. PMI Preclinical
  496. PPD
  497. PQE Group
  498. PRA Health Sciences
  499. PRADO
  500. PRC Clinical
  501. Preclinical Medevice Innovations
  502. PreClinical Pathfinder
  503. Pre-Clinical Research Services
  504. Premier Research
  505. Primacyt
  506. proDERM
  507. Regulatory Affairs Professionals Society
  508. Profil 
  509. ProMedica
  510. ProMedoss
  511. PROMETRIKA
  512. ProPharma Group
  513. ProRelix Research
  514. ProSciento
  515. Prosoft Clinical
  516. ProtoMed
  517. ProTrials
  518. Proxima Clinical Research
  519. Pharmaceutical and Regulatory Services
  520. Q&R Canada
  521. QA Consulting
  522. QAdvis
  523. Qmed Consulting
  524. QPS
  525. Qserve Group
  526. Q-Trials
  527. QUADRO CRO
  528. Qualitiso
  529. Quality and Compliance Consulting
  530. Qualtech
  531. Quanticate
  532. QUNIQUE 
  533. QVigilance
  534. R & C Consulting 
  535. R&G PharmaStudies
  536. RAHE Life Science
  537. RAMED
  538. Ratos
  539. RAY
  540. RCQ Solutions
  541. RCRI
  542. RCTs
  543. Reg-Affairs & QualiPractixis
  544. RegDesk
  545. Registrar Corp
  546. Regulatory Compliance Associates
  547. Regulatory Insight
  548. Reimbursement Strategies
  549. Reliance Life Sciences
  550. Research Professionals
  551. Rho
  552. RJR Consulting
  553. Rocketpharm
  554. Rook Quality Systems
  555. Rotrial Contract Research
  556. RQM+
  557. RQMIS
  558. RQSolutions
  559. RTI Health Solutions 
  560. Scandinavian CRO
  561. Scandinavian Regulatory Services
  562. SCiAN Services
  563. SCIderm
  564. SCIRENT
  565. Scope International
  566. SDC
  567. SeerPharma
  568. Sentez CRO
  569. Seoul CRO
  570. SEQ 
  571. SGS
  572. Shanghai QiSheng Business Consulting
  573. Shenzhen Advanced Medical Services
  574. Sidley Austin
  575. Simmons & Simmons
  576. SIPRA LABS
  577. SIRO Clinpharm
  578. Siron Clinical
  579. Sixmurs Group
  580. SLF
  581. Smerud Medical Research
  582. Smith+Nephew
  583. SMS-Oncology
  584. Sourcia
  585. Southern Star Research
  586. SPARTA
  587. Specipig
  588. Spectrum Clinical Research
  589. SPharm
  590. SPRIM Advanced Life Sciences
  591. SRD
  592. SRG Healthcare
  593. Stanford University
  594. StarFish Medical
  595. Stat One
  596. STATKING Clinical Services 
  597. Steinberg Research Solutions
  598. SteriPack Group
  599. SterlingBio
  600. Strategic Compliance International
  601. StrugoPharm
  602. Sumika Chemical Analysis Service
  603. SunFlare
  604. Surpass
  605. Surpass-Silicon Valley
  606. Symbio
  607. Symbion Research
  608. Syncorp Health
  609. Syneos Health
  610. Syntactx
  611. Syntax
  612. Synteract
  613. Syreon
  614. Szasz&Co.
  615. TAB Clinical
  616. Target Health
  617. TCA Clinical Research
  618. Technical Resources International
  619. TechnoSTAT
  620. TentaMedix
  621. TFS HealthScience
  622. The Clinical Trial Company 
  623. The CRO Group
  624. The Medical Affairs Company
  625. Thema Med
  626. Theo Manufacturing 
  627. Theorem Clinical Research
  628. TheraGenesis
  629. Therapeutics
  630. Think Research
  631. Tigermed
  632. Toolbox
  633. Toxikon
  634. TransPerfect Life Sciences
  635. Trial Form Support International
  636. Trial Runners
  637. Triangle Research Solutions
  638. TriMetis
  639. Turacoz Healthcare Solutions
  640. TÜV SÜD-Healthcare & Medical Devices
  641. Underwriters Laboratory
  642. Unikal Consultants
  643. University of California
  644. VA Office of Research and Development
  645. Valliscor
  646. Vantage BioTrials
  647. Vastrax
  648. Veeda Clinical Research
  649. Venn Life Sciences
  650. Veristat
  651. VIMTA 
  652. Visioncare Research
  653. vivo Science (a Texcell acquired company)
  654. Vivotecnia
  655. VOLER Biotech Consulting
  656. Vyomus Consulting
  657. WCCT Global
  658. WCG ThreeWire
  659. WDB Holdings
  660. Winicker Norimed
  661. Wipro
  662. Wonderville
  663. Woodley BioReg
  664. Worldwide Clinical Trials
  665. WuXi AppTec
  666. Zi-Medical
  667. Zimmer Biomet
  668. Zwiers Regulatory Consultancy

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com